Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Production / Operations Routine +

VVT Med Announces First Patients Treated with VVT's ScleroSafe(TM) System in Italy

Operational Milestone Achieved Amidst Regulatory Overhang

By The Northwire Desk — AI Analysis May 26, 2026 · 08:00 VVTM · 0.17 VVT Med Inc.
Executive Summary
  • VVT Med announced the successful treatment of the first group of patients in Italy using its ScleroSafe™ System at Fondazione Villa Salus Hospital in Mestre, Venice.
  • The procedure was conducted by Dr. Luca Palombi and his team in collaboration with local distributor Uber Ros S.p.A.
  • This event marks a significant milestone in the company's European expansion following the distribution agreement signed on April 27, 2026.
  • The technology utilized is non-thermal, non-tumescent (NT-NT), enabling controlled sclerosant delivery with simultaneous blood aspiration without thermal energy or tumescent anesthesia.
  • CEO Erez Tetro expressed encouragement regarding growing interest in ScleroSafe among leading vein specialists in Europe and highlighted Italy as an important market for advanced venous care.
Material Impact
  • The news confirms the commercial execution of the distribution agreement signed on April 27, 2026, with Uber Ros S.p.A., which was previously rated Routine - Positive.
  • While clinically significant, this operational update does not resolve the ongoing Management Cease Trade Order (MCTO) issued by the BCSC on May 1, 2026, due to continuous disclosure defaults.
  • The MCTO remains in effect until audited financial statements for FY 2025 and interim filings for Q1 2026 are completed by June 29, 2026.
  • Trading restrictions on the CEO and CFO remain active, limiting insider trading activity and potential equity-based incentives during this period.
  • The positive clinical milestone is incremental to previous announcements regarding distribution partners (India in Nov 2025, Italy in April 2026) rather than a new market-moving event.
  • Given the regulatory overhang, the market impact is likely muted compared to the operational progress, as compliance risks remain unresolved.
VVTM · Price
Company Overview
  • Company: VVT Med Inc., focused on venous disease treatment solutions.
  • Flagship Product: ScleroSafe™ System, a catheter-directed sclerotherapy system for varicose veins.
  • Technology: Non-thermal, non-tumescent (NT-NT) solution allowing simultaneous sclerosant injection and blood aspiration.
  • Regulatory Status: FDA-cleared and CE-marked; received CDSCO approval in India in 2022.
  • Current Operations: Commercial rollout active in Europe (Italy, North Macedonia), India, and the U.S. (NorthWell Health).
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 12, 2026 · 17:00

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

Regulatory Jun 11, 2026 · 08:30

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

Financings May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 15, 2026 · 17:31

Governance Risks Persist Despite Commercial Traction

Regulatory May 01, 2026 · 19:44

VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

Regulatory